Fasturtec bør ikke anvendes til patienter med glukose- 6- fosfat- dehydrogenasemangel (G6PD) eller andre metaboliske lidelser, der vides at forårsage hæmolytisk anæmi (blodmangel på grund af for hurtig nedbrydning af de røde blodlegemer).
Fasturtec should not be used in patients with a deficiency in glucose-6-phosphate dehydrogenase (G6PD) or other metabolic disorders known to cause haemolytic anaemia (low red blood cell counts, caused by the cells being destroyed too soon).